
SUPPLEMENTARY FIGURES

Author	Patient		Hazard ratio P value	
Breast cancer				
Robson, M. 2017	164	_	0.54 (0.37, 0.79)	
Han, H. S. 2018	104	_	0.75 (0.45, 1.22)	
Litton, J. K. 2018	183	_	0.59 (0.39, 0.90)	
Dieras, V. 2020	266	- _	0.72 (0.52, 0.97)	
Subtotal (I2 = 0%, p = 0.611)	717	-	0.64 (0.53, 0.78) <0.001	
Ovarian cancer				
Coleman, R. L. 2017	117	←−−	0.32 (0.19, 0.53)	
Moore, K. 2018	279	_	0.40 (0.29, 0.56)	
Coleman, R. L. 2019	137	-	0.38 (0.23, 0.63)	
Subtotal (I2 = 0%, p = 0.772)	533	-	0.38 (0.29, 0.48) <0.001	
0.20 0.50 1.0 1.5				

Supplementary Figure 1. PFS of breast or ovarian cancer patients with BRCAm1 treated with PARPis.

Author	Patient		Hazard ratio P value
Breast cancer			
Robson, M. 2017	129	-	0.68 (0.45, 1.07)
Han, H. S. 2018	90	_	0.78 (0.43, 1.42)
Litton, J. K. 2018	225	_	0.47 (0.32, 0.70)
Dieras, V. 2020	253	- _	0.66 (0.48, 0.89)
Subtotal (I2 = 0%, p = 0.415)	697	-	0.62 (0.51, 0.76) <0.001
Ovarian cancer			[
Coleman, R. L. 2020	79	←=	0.12 (0.06, 0.26)
Moore, K. 2018	101	e	0.20 (0.10, 0.38)
Coleman, R. L. 2019	61	_	→ 0.64 (0.27, 1.56)
Subtotal (I2 =76.2%, p = 0.015)	241		0.24 (0.10, 0.59) 0.002
	C	0.10 0.50 1	.0 1.5

Supplementary Figure 2. PFS of breast or ovarian cancer patients with BRCAm2 treated with PARPis.



Supplementary Figure 3. Begg's funnel plot for publication bias test for survival of breast cancer group (A, C) and ovarian cancer group (B, D) with BRCAm.